Osmol Therapeutics

Osmol Therapeutucs, Inc. (New Haven, CT) is developing a therapy discovered at Yale University by Professor Barbara Ehrlich and licensed to the company for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment. Currently, there are no approved drugs for these indications. Osmol closed a Series A Preferred Stock financing at the end 2016 that was led by Elm Street Ventures and Koax Investment Partners. ESV Venture Partner Brian R. Dixon, PhD is President and CEO of Osmol.